Granted Patent B2

US 12,281,160 · App. 16/982,762 · Granted Apr 22, 2025

Inventors: Nicholas Wilson (Melbourne, AU); Steven Bozinovski (Melbourne, AU)

Assignee: CSL LIMITED

C07K16/243A61P11/06C07K16/2866A61K2039/505C07K2317/34C07K2317/565C07K2317/622C07K2317/76

Abstract

Claims (25)

1. A method for treating asthma in a subject, the method comprising administering an antibody that binds to granulocyte colony stimulating factor receptor (G-CSFR) and inhibits granulocyte colony stimulating factor (G-CSF) signaling, wherein the antibody comprises:

(a) a heavy chain variable region (VH) comprising three CDRs of a VH comprising an amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region (VL) comprising three CDRs of a VL comprising an amino acid sequence set forth in SEQ ID NO: 5; or

(b) a VH comprising three CDRs of a VH comprising an amino acid sequence set forth in SEQ ID NO: 2 and a VL comprising three CDRs of a VL comprising an amino acid sequence set forth in SEQ ID NO: 3.

2. The method of claim 1 , wherein the asthma is allergic asthma.

3. The method of claim 1 , wherein the asthma is neutrophilic asthma.

4. The method of claim 1 , wherein the asthma is severe asthma.

5. The method of claim 1 , wherein the subject has airway bacterial colonisation and/or a respiratory viral infection.

6. The method of claim 1 , wherein the antibody is administered in an amount sufficient to prevent or reduce the severity of an asthma exacerbation.

7. The method of claim 1 , wherein the antibody is administered in an amount sufficient to reduce or prevent neutrophilic lung inflammation.

8. The method of claim 1 , wherein the antibody is administered in an amount sufficient to reduce or prevent airway hyper-responsiveness (AHR).

9. The method of claim 1 , wherein the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in mucus production.

10. The method of claim 1 , wherein the antibody is administered in an amount sufficient to have one or more of the following effects in the subject's lung:

(i) Reduce or prevent an increase in neutrophil levels;

(ii) reduce or prevent an increase in neutrophil elastase levels;

(iii) reduce or prevent an increase in extracellular double stranded DNA levels;

(iv) reduce or prevent an increase in eosinophil levels; and

(v) reduce or prevent an increase in T H 2 cell levels.

11. The method of claim 1 , wherein the antibody comprises a VH comprising an amino acid sequence set forth in SEQ ID NO: 4 and a VL comprising an amino acid sequence set forth in SEQ ID NO: 5.

12. The method of claim 1 , wherein the antibody comprises a VH comprising an amino acid sequence set forth in SEQ ID NO: 2 and a VL comprising an amino acid sequence set forth in SEQ ID NO: 3.

13. The method of claim 1 , wherein the antibody comprises:

(i) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 14 or 18 and a light chain comprising an amino acid sequence set forth in SEQ ID NO: 15; or

(ii) one heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 14 and one heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 18 and two light chains comprising an amino acid sequence set forth in SEQ ID NO: 15.

14. A method for treating asthma in a subject, the method comprising administering an antibody which comprises a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 14 or 18 and a light chain comprising an amino acid sequence set forth in SEQ ID NO: 15.

15. The method of claim 14 , wherein the subject is human.

16. The method of claim 15 , wherein the asthma is severe.

Assignments (2)

Priority Claims (1)

Continuity (1)

References Cited (147)